Xsensio is a Lausanne-based deep-tech company building Lab-on-Skin, a wearable biosensing device that continuously measures multiple biochemical biomarkers to inform clinical decision-making. The platform delivers near real-time, multi-modal biochemical data that has traditionally been inaccessible at the point of care, enabling more personalized and preventive healthcare. Spun out of academic research, Xsensio collaborates with leading hospitals and industrial partners to validate and scale its technology. A newly announced long-term partnership with Texas Instruments will leverage TI’s semiconductor expertise to miniaturize and manufacture the biosensing system at scale. The firm has been recognized by TIME as one of the World’s Top HealthTech Companies of 2025. With its recent $7 million Series A, Xsensio is well-capitalized to accelerate clinical deployment and industrial scalability of its platform. The oversubscribed round underscores investor confidence in Xsensio’s progress and market potential.

Total raised

$12M

Funding rounds

2

Latest round

Series A

Latest activity

Mar 2026